Skyrizi has also been approved to treat Crohn's Disease, an added bonus and another multi-billion dollar market. These are Immunology, Oncology, Neurology, Virology and Eye Care. In this post I model AbbVie product sales to 2030 - including pipeline assets - and use discounted cash flow analysis to calculate a present day share price target. How to Decide, Taiwan Semiconductor Manufacturing Expanding in the West, One Way to Earn More From Dividend Stocks, How to Choose a Winning Dividend Investing Strategy, 3 Industries Leading the Stock Market Rebound, Oil Tankers Boost Dividends, See Continued Robust Business In '23. AbbVie has said it expects to generate high-single-digit CAGR growth from 2025 to the end of the decade after revenues fall in 2023 due to Humira LOE. AbbVie's post-Humira LOE plans are not riskless, and its targets are ambitious, but nevertheless I see no harm in picking up shares in the Pharma at the current price, accepting a generous 4% dividend, and likely benefitting from share repurchases and a steadily growing share price until 2030. We expect that to happen in 2027 with continued significant growth anticipated in the following years. You should never invest money you cannot afford to lose. The company reported $3.60 EPS for the quarter, topping the consensus estimate of $3.54 by $0.06. AbbVie's total revenue grew a solid 51% to $50.2 billion over the last twelve month period, compared to $33.0 billion in 2019. Noting the stellar earnings reported by the firm in the first quarter, Richard A. Gonzalez, chairman and CEO of AbbVie, said: An overview of the companys net revenue in Q1 shows a major portion of revenue came from its immunology portfolio, which brought in $6.14bn. AbbVie had a net margin of 20.39% and a trailing twelve-month return on equity of 154.52%. All content of the Dow Jones branded indices S&P Dow Jones Indices LLC 2019 and/or its affiliates. I suspect Eye Care is a division AbbVie can turn around given time, and I feel that with regards to oncology, where AbbVie has the strongest pipeline assets - lymphoma bispecific Epcoritamab may be approved to treat large B-cell lymphoma, and peak sales estimates range from $1.5 - $3bn, although AbbVie will not earn all of that since the product is co-developed with Genmab. In my last note on AbbVie (NYSE:ABBV) for Seeking Alpha - in early July - I reviewed the Big Pharma's Q1'22 earnings and looked ahead to the release of Q2'22 figures. That reflects uncertainty about what the future holds for AbbVie. The acquisition expanded AbbVies neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies. For ABBVIE INC stock forecast for 2023, 10 predictions are offered for each month of 2023 with average ABBVIE INC stock forecast of $156.58, a high forecast of $160.07, and a low forecast of $152.24. The company projects the U.S. toxin market (where Botox is the top product) will decline by mid-single digits. As we can see above one of either Skyrizi or Rinvoq has now been approved for all of the same indications as Humira is, except for Hidradenitis Suppurativa, although Rinvoq is undergoing a Phase study in this indication. 326 E 8th St #105, Sioux Falls, SD 57103 Although Wallet Investor did not provide targets for 2030, its longer-term Abbvie stock prediction expected the price to hit $300.386 in June 2027. I take the total revenue figure from each year and plug it into an income statement forecast as follows: AbbVie income statement forecast. The CEO, speaking at a fireside chat during the conference, commented: we remain well-positioned to absorb the impact from the Humira LOE and quickly return to strong growth starting in 2025. The consensus among Wall Street research analysts is that investors should "hold" ABBV shares. Not only do these companies pay handsome dividends, they typically grow revenues every year and generate wide profit margins which leads to share price upside. The next two approvals - for Navitoclax in Myelofibrosis and Teliso V in non squamous non-small cell lung cancer ("NSCLC") - are anticipated by management in 2024. The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". AbbVie is one of the largest global Pharmaceuticals, with a market cap of >$265bn. Our Product Disclosure Statement (PDS) and Target Market Determination provides important information about our products and who our products are more likely to be suited to Capital.com does not provide financial or investment advice and you should seek independent advice if you are unsure of the risks or whether our products are suitable for you. The company didn't offer a . The S&P 500 (US500) lost 9.1%, the Dow Jones (US30) slid 9.7%, and the Nasdaq Composite fell 23% during the same period. The fact that my own forecasts are less ambitious than management's reflects the fact I have not introduced new products into my forecasts, and it will be interesting to see how management performs on that front as AbbVie has not really had to have a string pipeline while Humira has delivered such dominance in the auto-immune markets. In my model I have then reduced revenues by 20% between 2024 - 2026, and then by 10% per annum between 2027 - 2030. I look forward to seeing if Epcoritamab is approved this year, and although there is not a lot else in the near-term pipeline at this time, I also look forward to seeing how other projects may progress, e.g., opportunities in Parkinson's Disease, Alzheimer's and Cystic Fibrosis. In the past I have written about the high level of competition between major Pharma in the auto-immune space - for example, for Psoriatic Arthritis the list of approved drugs includes Humira, UCB Pharma's Cimzia, Amgen's Enbrel, Johnson & Johnson's (JNJ) Stelara, Eli Lilly's (LLY) Talzt, Novartis' (NVS) Cosentyx and Bristol-Myers Squibb's (BMY) Orencia. The median estimate represents a +5.72% increase from the last price of 156.07. Based on an average daily volume of 5,600,000 shares, the days-to-cover ratio is currently 2.1 days. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each. However, there are some general principles that can be followed in order to improve the accuracy of stock price predictions. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. Venclexta continues to pick up momentum with sales up 16% to >$500m in Q2'22, and I forecast the drug to exceed $3.2bn in revenues by the end of the decade. Specifically, they have bought $0.00 in company stock and sold $23,102,528.00 in company stock. I am not receiving compensation for it (other than from Seeking Alpha). Out of the most recent ratings, BMO Capital Markets Gary Nachman raised its price target from $161 to $174 with an outperform rating, while Truist Financial analyst Robyn Karnauskas raised the Abbvie stock prediction from $118 to $135 while raising rating to a buy. Teliso V is an antibody drug conjugate and a c-Met inhibitor. Finally I can present a target price for AbbVie stock in 2023 using DCF / EBITDA analysis. As per management's guidance, I am modelling for $5.7bn of revenues in 2023, with growth beginning to accelerate substantially from 2025 / 26 onwards. Fortunately for AbbVie shareholders Gonzalez and his management team have had many more years than expected to prepare for Humira's Loss of Exclusivity ("LOE"), and it has never been the Pharma's ambition to build its business around a single, all-conquering but time-limited drug. The AbbVie of today has 5 thriving divisions - Immunology, Oncology, Neuroscience, Aesthetics, and Eye Care - with the latter 3 divisions acquired from Allergan as part of AbbVie's $63bn takeover of that company. How often does AbbVie pay dividends? About the AbbVie, Inc. stock forecast. Factset: FactSet Research Systems Inc.2019. Shareholders of record on Friday, April 14th will be given a dividend of $1.48 per share on Monday, May 15th. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents, Timothy J Richmond and Timothy J Richmond. I'm on twitter @edmundingham. Please disable your ad-blocker and refresh. Enjoy your holiday weekend and catch up on our most read stories this week. All rights reserved. Our daily ratings and market update email newsletter. Compare Top Brokerages Here. AbbVie is a leading dividend payer. Having so much debt in a prevailing inflationary environment is also unattractive. I have no business relationship with any company whose stock is mentioned in this article. In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Investors needn't panic however - Humira's replacements are expected by AbbVie's CEO to generate even higher revenues per annum. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. That figure suggests a forward Price to Earnings ("P/E") ratio of ~10x, which is well below the US Big Pharma sector average of ~23x, although it should be noted that the GAAP/non-adjusted EPS may be only significantly lower than the adjusted figure, based on adjusted EPS of $6.52 across H1'22, and GAAP EPS of $3.03 over the same period. The company is a member of the Fortune 100 and one of the Fortune 100s Best Companies To Work For. With a 5-year investment, the revenue is expected to be around +88.28%. I am not receiving compensation for it (other than from Seeking Alpha). (my tables). On the negative side of things, we can see that AbbVie is no longer breaking out sales within its Women's Health division, with revenues lumped into the "all other section, presumably. In the last four years, Johnson & Johnson's Free Cash Flow has fallen from $18.53B to $17.00B - a 8.28% decrease. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions. I will conclude this analysis by stating that, based on all available information, market headwinds and tailwinds, competitors, and opportunities via its products and pipeline, I still consider AbbVie to be a strong investment opportunity. AbbVie Stock: ABBV Overview and Dividend Potential, Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor (ABBV), Analyst Confidence in Eli Lilly Boosted by Product Pipeline (ABBV), Johnson & Johnson: Taking The Bull By The Horns? The other major plus is probably the performance of the neuroscience divisions, where as we can see, Botox (indicated for migraine treatment), atypical antipsychotic Vraylar, migraine therapy Ubrelvy and newly launched Qulipta, an oral CGRP inhibitor indicated for chronic migraine all delivered good sales growth. The average price target is $163.64 with a high forecast of $190.00 and a low forecast of $133.00. As well as the stock price gains AbbVie has always paid a handsome dividend - which has increased by 270% since the Pharma's inception, currently paying $1.48 per quarter, for a current yield of 4% - the highest in the large Pharmaceutical sector. The review period was extended by three months in order for the FDA to review additional data submitted by AbbVie. During the same quarter in the prior year, the firm posted $3.31 EPS. (my tables and forecasting). The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049. Get short term trading ideas from the MarketBeat Idea Engine. The P/E ratio of AbbVie is 23.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.03. AbbVie has fought off patent challenges against Humira for years longer than expected, and despite losing exclusivity in Europe in 2020, a series of price hikes and market dominance in the US in indications such as Rheumatoid Arthritis ("RA"), Psoriatic Arthritis ("PsA"), Crohn's Disease ("CD"), and Ulcerative Colitis ("UC") - have enabled the drug's sales revenues to keep growing. Aurora Cannabis Revenue Forecast for 2023 - 2025 - 2030. We have also launched Skyrizi for PSA in rheumatology, where we're seeing strong utilization, which is driving accelerated share growth. Shares of ABBV stock can be purchased through any online brokerage account. American biopharmaceutical company Abbvie (ABBV) has surged nearly 13% year to date (YTD), and 35% year-over-year (YOY), as of 30 June. Read our dividend analysis for ABBV. Since its 2013 separation from Abbott Laboratories (ABT 1.78%), AbbVie's stock has grown more than 160%. Identify stocks that meet your criteria using seven unique stock screeners. ET comments The company's lead asset - all-time best selling immunology drug Humira - finally loses patent protection this year and sales will enter a period of terminal decline. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The major market events for the week ahead right in your inbox. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. Since then, however, the stock price has fallen 18% to its current price of $142.6. Get daily stock ideas from top-performing Wall Street analysts. The division delivered >$1.65bn in sales in Q2'22, up >15% year-on-year, and with Vraylar, Ubrelvy and possibly Qulipta all earmarked for blockbuster sales - $4bn in the case of Vraylar - my forecasting suggests this division could double in size by 2030, from ~$6.6bn revenues generated in FY22, to >$13.5bn by 2030. ABBV closed at $152.49 on 29 June, which was above its 200-day moving average (MA) of 136.42, indicating a bullish signal for the stocks price movement ahead, according to data from TradingView. I wrote this article myself, and it expresses my own opinions. With AbbVie seemingly very confident of approvals for all 3 of these drugs, and Gonzalez suggesting they could form the basis of a "$6 billion kind of franchise" I have modelled for such an outcome by 2030. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Their combined revenues are expected to reach $7.5bn in 2022, and Gonzalez told the audience at JPM that: Skyrizi and Rinvoq are now on pace to deliver more than $17.5 billion in combined sales, risk adjusted sales in 2025, well above our previous expectations. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. You should consider whether you understand how CFDs work and can afford the risks. View which stocks are hot on social media with MarketBeat's trending stocks report. Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. AbbVie's stock was trading at $161.61 on January 1st, 2023. Under the terms of the resolution, AbbVie will grant Alvotech a non-exclusive licence to its Humira-related patents in the US, which will begin on 1 July 2023. Johnson & Johnson Free Cash Flow Forecast for 2023 - 2025 - 2030. 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. Whether these factors make ABBV a good investment for you or not will depend on your portfolio composition, investment goals and risk profile, among other factors. AbbVie stock is one of the most well-known pharmaceutical companies. The company issued revenue guidance of -. AbbVie will have to drop its price point to compete with the generics however, plus there is the 10% of the market it is not covered for, so an overall 20% decline in revenues in 2023 seems accurate. approvals of Humira, Skyrizi, Rinvoq (AbbVie JPM Healthcare conference presentation). Free Stock Analysis Report: See The True Value of Any Stock, The Best Strategy For Your Small Trading Account. losed Joint Stock Company FinTech Solutions, Fidelity NASDAQ Composite Index Tracking Stock Fund, Abbvie stock price analysis: Past year performance, Abbvie fundamental analysis: Q1 2022 earnings, Abbvie stock forecast: Company guidance and analysts predictions. The eye-disease markets are very large - Regeneron's Eylea is a >$7bn per annum selling drug and AMD markets are >$20bn in size. Between September 2021 and April 2022, AbbVie stock went on a sensational bull run, gaining 62% and hitting an all-time peak of $174. With the Hughes Optioneering Strategy, youll soon learn that the safest option for new accounts is options themselves! In the next year, analysts expect Free Cash Flow to reach $26.97B - an increase of 58.68%. Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most. I'll also share some a forward income statement and discounted cash flow analysis that suggests the present value of AbbVie shares ought to trade as high as $176, implying that shares are presently discounted by as much as 18% to their true worth. AbbVie has 5 focus areas for its research and products. With no LOEs on the horizon, it is relatively plain sailing for the company ex-Humira, and the performance of Skyrizi and Rinvoq - to date at least - suggests management does have this massive patent cliff covered. Ltd., AbbVie Overseas S. r.l., AbbVie Oy, AbbVie Participaes Ltda., AbbVie Pharmaceutical Trading (Shanghai) Co. Ltd., AbbVie Pharmaceuticals B.V., AbbVie Pharmaceuticals GmbH, AbbVie Pharmaceuticals LLC, AbbVie Pharmaceuticals SCA., AbbVie Pharmaceuticals Societe Anonyme, AbbVie Polska Sp. Investors do not seem to be taking the bait, however, as AbbVie's share price has slipped by >7% across the past month, and >5% across the past 5 days. GSK Free Cash Flow Forecast for 2023 - 2025 - 2030. AbbVie says it will pay down debt of $4bn in 2023, which will "bring cumulative debt pay down ~$34bn", but the company is heavily reliant on maintaining an investment grade rating. 67.71% of the stock of AbbVie is held by institutions. 1 dividend stock for a LIFETIME of income. 580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. The lowest target is $136.35 and the highest is $210. I wrote this article myself, and it expresses my own opinions. According to CompaniesMarketCap, the biopharmas market capitalisation stood at $272.38bn, making it the worlds 30th most valuable company. The company had recorded a $4.7 billion increase in the contingent consideration liability related to Skyrizi last year. Snowflake Reports Weak Guidance: Is the Growth Snowflake Melting? The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. Ever since its split from Abbott Laboratories (ABT) in 2012 AbbVie (NYSE:ABBV) has delivered strong returns for investors - its stock price having risen overall from $30, to $149 per share at the time of writing - trading down slightly from its all-time high of >$160 achieved in early December last year. target price for AbbVie stock based on DCF / EBITDA multiple analysis (my table and assumptions). The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. Receive regular, detailed analysis focused on biotech and healthcare stocks. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Their ABBV share price forecasts range from $140.00 to $200.00. American Consumer News, LLC dba MarketBeat 2010-2023. View analysts price targets for ABBV or view top-rated stocks among Wall Street analysts. Slide from JPM Conference 2022 presentation. I have no business relationship with any company whose stock is mentioned in this article. Note that analysts ABBV stock forecasts can be wrong. AbbVie is led by CEO and Chairman Rick Gonzalez - likely the only Pharma CEO who lacks a college degree - who has successfully defended Humira from generic drug competition by adopting a controversial strategy of continually applying for new patents related to minor changes in manufacturing methods or administration, often referred to as a "patent thicket". In the next year, analysts predict that Revenue will reach C$253.83M - an increase of 3.50%. The companys operations span 20 countries, treating more than 60 million people and 40 conditions annually. The majority of the biosimilar (more sophisticated versions of generic drugs) imitations of Humira that will contest for market share with the original will launch around the middle of 2023, including versions developed by Pfizer (PFE), Boehringer Ingelheim, Organon (OGN), Biocon, Coherus Biosciences (CHRS) and Sandoz, whilst Amgen's (AMGN) Amjevita is permitted to launch in January. On average, analysts rate AbbVie stock as a buy. The companys original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. Forecast . Although management reminded analysts that "Imbruvica continues to be the total market share leader across all lines of therapy in CLL", the outlook does not look especially promising. Both of these assets appear to be doing the job they were intended for - protecting AbbVie's dominance in various auto-immune markets - and now represent ~13% of AbbVie's total revenue generation. Abbvies first quarter 2022 financial results for the quarter ended 31 March revealed that diluted earnings per share (EPS) increased to $2.51 on a generally accepted accounting principles (GAAP) basis, up from $1.99 a year earlier. The most recent increase was . AbbVie Stock Forecast 2022 - 2025 - 2030 | StockForecast.com GB To summarize, although AbbVie does not have the same clout in oncology as it does in immunology - as evidenced perhaps by the declining sales of Imbruvica - it is clearly an area of focus for management. With AbbVie's revenues accelerating past $80bn in 2030 (by my calculation), and cash flow generated in that year being >$25bn, after applying discount factors for each year I reach a price target of $176 - the average of DCF - $162 per share - and EBITDA - $189 per share - calculations. It's hard to argue against Skyrizi and Rinvoq's performance to date, however, and with the total addressable market across all immunology indications likely well in excess of $100bn, I feel fairly comfortable that AbbVie can grow this division's revenues even as the world's biggest ever selling drug exits stage left. AbbVie stock forecast 2022 - 2025 - 2030 with analysis AbbVie stock stood at $162.110000610352 on 2022-03-31. forecast for 2023 is $159.42, forecast for 2024 is $156.65, forecast for 2025 is $139.68, forecast for 2026 is $124.48, Both Leqembi and Donanemab are potential $5bn - $10bn selling assets, but both drugs still have safety questions to answer and not certain to be made eligible for reimbursement. Please. This suggests a possible upside of 3.2% from the stock's current price. For the next year, analysts predict that Free Cash Flow will reach 6.91B - an increase of 1.94%. Abbvie has a strong pipeline of projects ahead, and has recently received US FDA approval of its ulcerative colitis drug Rinvoq. ABBV has several positive factors pushing its price performance. I/we have a beneficial long position in the shares of ABBV, BMY either through stock ownership, options, or other derivatives. The obvious advantages of a "one and done" permanent cure make them potentially very lucrative therapies. According to 34 stock analysts, the average 12-month stock price forecast for AbbVie stock is $166.14, which predicts an increase of 7.62%. The company employs 50,000 workers across the globe. Always conduct your own due diligence before investing. Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T), Bristol-Myers Squibb (BMY), Wheaton Precious Metals (WPM), Rogers Communications (RCI) and Open Text (OTEX). Outside of Humira, management does not have to worry about LOEs for any of its other portfolio products before the end of the decade, which is encouraging, however, based on my own projections of how AbbVie will generate its revenues between 2023 and 2030, if management wants to drive a CAGR in the high single digits after 2025, it will need some help from its pipeline - not an area of particular strength for AbbVie. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. I write about Biotech, Pharma and Healthcare stocks and share investment tips. Forecast target price for 03-06-2023: $ 152.58. call (03) 8658 0539 support.au@capital.com. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. Sales are expected to recover in H2'22, however, and forecast year-on-year growth. Most stock quote data provided by BATS. As we can see the immunology division consists of only 3 assets yet by my calculation, will likely account for 50% of AbbVie's revenues in 2022 (to calculate 2022 sales revenues by product, since we do not yet have final figures, I have used 9m 2022 figures and assumed Q4 revenues will be the average of the previous 3 quarters). For the next nine years, the forecast is for Revenue to grow by 3.57%. For full year 2022, Abbvie predicted the adjusted diluted EPS guidance range at $14.00 to $14.20 and $13.92 to $14.12. In this article we take a closer look at the Abbvie stock forecast, after analysing the firms latest earnings, price moving news and analyst comments. There is no mention of Women's Health in the Q2'22 earnings call or in the 10-Q submission to the SEC, or any of the drugs within it, yet the divisions have not (to the best of my knowledge) been sold, despite rumors it was put up for sale at ~$5bn. Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. (JPM Healthcare conference presentation), Skyrizi's performance has been particularly eye-catching. The company's average rating score is 2.44, and is based on 7 buy ratings, 9 hold ratings, and no sell ratings. According to AbbVie CEO Rick Gonzalez, speaking on the Q2'22 earnings call, "Skyrizi's total prescription share of the U.S. biological market (in psoriasis) has increased to approximately 26%", and". This has been in spite of a string of macroeconomic headwinds such as the ongoing Russia-Ukraine war that has contributed to record high inflation in the US and the UK, and the companys psoriatic arthritis drug Adalimumab, known as Humira, facing biosimilar rivals in the US from 2023. That is interesting to me as I think it suggests management will need to commercialize more assets if it wants to hit that target. Disclosure: I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. I believe AbbVie is likely 15 - 20% undervalued at current price. All rights reserved. ABBV currently yields 4.1% and has raised its dividend every year since 2013. The consensus rating was moderate buy based on 16 analysts ratings, with 10 recommending buy, five hold and sell. AbbVie saw a increase in short interest in February. The average price target represents a 6.33% change from the last price of $153.90. I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. If you have an ad-blocker enabled you may be blocked from proceeding. At their peak, according to a slide from AbbVie's presentation at the JPMorgan (JPM), these 2 drugs are expected to generate more revenues than Humira at its peak. See AbbVie Inc. (ABBV) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. All rights reserved. Past performance is no guarantee of future results. Perhaps this is an example of how ruthless management can be when encountering falling sales, and a warning that not all company divisions are guaranteed to thrive. It had an upside potential of 4.76%, based on the closing price of $152.49 on 29 June. Abbvie Stock Forecast 2023 In the Biopharmaceutical Industry, Abbvie has been able to create a leadership position in the market in each business segment with different brand names in different business categories like Immunology, Hematologic Oncology, Neuroscience, Aesthetics, and Eye Care. I am not receiving compensation for it (other than from Seeking Alpha). Trading CFDs is high risk and is not suitable for everyone. This would represent an increase of 1.78%. The pharma industry witnessed solid growth amid the pandemic. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Having dived into the numbers however and looked ahead to 2030 through the eyes and guidance of management, my conclusion is that investors can probably buy AbbVie stock at current price with reasonably high hopes of making a decent ROI - perhaps 15 - 20% in the next 12 - 18 months, whilst also benefiting from a generous dividend. In other words, management believes the LOE of Humira - despite it being the world's best-selling drug - will not hinder growth at the company. That led to an overall 6% year-on-year gain of 6%, and a 13% sequential gain.
A Charge Nurse Is Making Client Care Assignments,
Which Quotation Best Exemplifies The Indifference,
Hangman Sequel Karl Urban,
Karla Ostrowsky Obituary,
Articles A